Wockhardt shares have recently experienced a significant surge, capturing the attention of investors and market analysts alike. The stock of this pharmaceutical company hit an all-time high of ₹1,809.95 in Wednesday's intraday trade, marking a rally of 17% on the BSE. This surge was supported by heavy trading volumes and a positive outlook for the company's business.

Over the past year, Wockhardt has delivered exceptional returns, zooming 207% against an 8% gain in the BSE Sensex. Looking at a broader timeframe, the stock has skyrocketed 956% from ₹171.45 on the BSE. This impressive performance positions Wockhardt as a multibagger stock within Rekha Jhunjhunwala’s portfolio, contributing significantly to its overall value.

Rekha Jhunjhunwala, a prominent investor and the wife of the late Rakesh Jhunjhunwala, held a 1.75% stake in Wockhardt as of March 31, 2025, which translates to 2.84 million shares. Her portfolio, which publicly holds 26 stocks, is valued at over ₹41,570.9 crore. It spans various sectors, including finance, auto, healthcare, and digital, with holdings in companies like Titan, Metro Brands, NCC, Indian Hotels Company, and Fortis Healthcare.

Wockhardt's strong performance in FY25 has been a key driver of its stock surge. The company reported a 67% year-on-year growth in EBITDA (earnings before interest, taxes, depreciation, and amortisation), reaching ₹418 crore, compared to ₹251 crore in the previous year. The EBITDA margin improved significantly to 13.8% from 8.7%. While revenue grew modestly by 5% year-on-year to ₹3,033 crore, the company managed to reduce its net loss to ₹57 crore from ₹472 crore in the previous year. These strong operational results have boosted investor confidence, leading to increased buying activity in Wockhardt shares.

The company's positive outlook is further supported by developments such as Zaynich, which is planned for filing in the USA by August 2025.

While Wockhardt has been a star performer, Rekha Jhunjhunwala's portfolio also includes other notable stocks that have contributed to her overall returns. Some of the top performers in her portfolio include Wockhardt Ltd with a 121.16% 1Y return, Va Tech Wabag Ltd at 76.78%, and Fortis Healthcare Ltd with 72.67%. Other gainers are Jubilant Pharmova Ltd (52.11%) and Raghav Productivity Enhancers Ltd (57.69%). Underperformers include Sun Pharma Advanced Research Co Ltd (-68.2%), Valor Estate Ltd (-53.76%), and Aptech Ltd (-47.89%).

Rekha Jhunjhunwala's investment philosophy is characterized by diversity, a long-term perspective, a focus on quality, active management, and trend spotting. She strategically diversifies her investments across various sectors, holds onto stocks for extended periods, invests in well-established companies with proven track records, actively manages her portfolio, and identifies and capitalizes on market trends.